Month: June 2024

Ipsen’s Iqirvo® (elafibranor) 80 mg tablets receives U.S. FDA accelerated approval as a first-in-class treatment for Primary Biliary Cholangitis (PBC) First-ever drug developed in-house by GENFIT to achieve U.S. FDA’s approval GENFIT is eligible to receive a €48.7 million milestone payment from Ipsen upon the first commercial sale of Iqirvo in the U.S., as well as tiered double-digit royalties of up to 20%Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 10, 2024 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the achievement of a historic corporate milestone: the U.S. Food and Drug Administration (FDA) accelerated approval of Iqirvo1 (elafibranor)2 80 mg tablets...

BOSTON, June 10, 2024 (GLOBE NEWSWIRE) — Tiber Ventures, Inc., formerly known as SeaChange International, Inc., (OTC: SEAC) (“Tiber Ventures”) today is announcing a modified “Dutch auction” tender offer to purchase with cash up to $6.16 million of shares of its common stock, at a price per share of not less than $6.75 and not more than $7.25. The complete terms of the tender offer are set forth in the Offer to Purchase and the related Letter of Transmittal, each dated today. The tender offer will expire one minute after 4:59 P.M. Eastern Daylight Time on July 10, 2024 unless extended by Tiber Ventures or otherwise terminated. Tenders of shares must be made on or prior to the expiration of the tender offer and may be withdrawn at any time prior to the expiration of the tender offer, in each case, in accordance...

                                                                        Iqirvo® (elafibranor) 80 mg tablets is the first new medicine approved in nearly a decade for the treatment of the rare liver disease called primary biliary cholangitis Approval based on positive Phase III ELATIVE trial data Primary biliary cholangitis impacts approximately 100,000 people in the US and is growing in global prevalence. If inadequately treated, it can cause liver failure U.S. approval of Iqirvo establishes Ipsen as a leader in the treatment of rare cholestatic liver diseasesPARIS, FRANCE, 10 June 2024 Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Iqirvo® (elafibranor) 80 mg tablets for the treatment of primary biliary cholangitis (PBC) in combination with...

NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) — Vornado Realty Trust (NYSE:VNO) announced today that its 52% owned street retail joint venture has completed a $400 million refinancing of 640 Fifth Avenue, a 315,000 square foot Manhattan office and retail property. The interest only, non–recourse loan carries a fixed rate of 7.47% and matures in July 2029. The street retail joint venture paid down by $100 million the prior $500 million loan, which was fully guaranteed by Vornado, bore interest at SOFR plus 1.11% and was scheduled to mature in August 2024. Vornado Realty Trust is a fully-integrated equity real estate investment trust. CONTACT Thomas J. Sanelli(212) 894-7000 Certain statements contained herein may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking...

Midland, Texas, June 10, 2024 (GLOBE NEWSWIRE) — Natural Gas Services Group, Inc. (“NGS” or the “Company”), a premier provider of natural gas compression equipment to the energy industry, announced today the closing of an expansion of its existing credit facility (the “Facility”) led by Texas Capital Bank. The Company added $75 million of additional borrowing capacity to increase the committed borrowing capacity to $300 million. The Facility provides the Company with additional capital to fund further growth in NGS’s rental equipment fleet.  “We are pleased to announce the successful expansion of our Facility from $225 million to $300 million,” said Justin Jacobs, Chief Executive Officer of NGS.  “I want to thank all of our lending partners for their continued support and hard work to allow us to reach this agreement to increase...

NHL and Rogers to Co-Host Free Concerts Outside Rogers Place Before Game 3 & 4 Rogers Holding National Customer Contest for Stanley Cup Final EDMONTON, Alberta, June 10, 2024 (GLOBE NEWSWIRE) — The National Hockey League (NHL) and Rogers today announced plans for the Rogers Festival at the Final concert series to celebrate the 2024 Stanley Cup Final between the Edmonton Oilers and Florida Panthers. Global superstar and five-time GRAMMY winner Shania Twain and four-time JUNO Award-winning rock band Our Lady Peace will headline free musical performances outside Rogers Place in Edmonton. Our Lady Peace will perform for fans before Game 3 on Thursday, June 13. Shania Twain will be the featured performer before Game 4 on Saturday, June 15. Both performances will begin at 4 p.m. MT in Scotiabank Fan Park outside Rogers Place before...

Mohammed G. (Rally) ZerhouniMiddlesex Water Names Mohammed G. (Rally) Zerhouni Chief Financial OfficerISELIN, N.J., June 10, 2024 (GLOBE NEWSWIRE) — Middlesex Water Company (NASDAQ: MSEX) has named Mohammed G. (Rally) Zerhouni as its new Senior Vice President, Chief Financial Officer and Treasurer effective June 24, 2024, as part of its ongoing strategic succession planning efforts. Zerhouni joins Middlesex following a comprehensive search for a successor to Senior Vice President, Treasurer and Chief Financial Officer, A. Bruce O’Connor, who will retire from the Company effective June 21, 2024, after 34 years of service. “I and the rest of the Middlesex Board of Directors are thrilled to have Mohammed G. (Rally) Zerhouni join our company. His breadth of knowledge and experience will play a key role in helping to address...

WINSTON-SALEM, N.C., June 10, 2024 (GLOBE NEWSWIRE) — ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease, today announced that it has commenced an underwritten public offering and a concurrent registered direct offering of up to an aggregate of $125 million of its Class A ordinary shares, before deducting underwriting discounts and commissions and other offering expenses. ProKidney expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the Class A ordinary shares sold in the underwritten public offering. All of the Class A ordinary shares in the underwritten public offering and concurrent registered direct offering are being sold by the Company. Certain investment entities, which includes...